Skip to main content
Jack Roth, MD, Thoracic Surgery, Houston, TX, University of Texas M.D. Anderson Cancer Center

JackRothMD

Thoracic Surgery • Houston, TX

Cardiovascular Surgery

Professor of Thoracic Surgery, University Tex Houston

Join to view full profile

Dr. Roth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Roth's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Thoracic Surgery, 1977 - 1980
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Surgery, 1975 - 1977
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineInternship, Transitional Year, 1971 - 1972
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1971

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1973 - 2023
  • TX State Medical License
    TX State Medical License 1986 - 2020

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • Top Doctors:SE Texas Castle Connolly, 2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Inhibition of thioredoxin/thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis  
    John V Heymach, Stephen G Swisher, Jack A Roth, John D Minna, Clinical Cancer Research
  • Landscape of EGFR -Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-Progression in EGFR-Mutant NSCLC  
    Stephen G Swisher, Vassiliki A Papadimitrakopoulou, John V Heymach, Jack A Roth, Jianjun Zhang, William N William, Bonnie S Glisson, Clinical Cancer Research
  • Validation of the 12-Gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer  
    Cesar Moran, Jack A Roth, Yang Xie, John D Minna, Vassiliki A Papadimitrakopoulou, John V Heymach, Stephen G Swisher, Clinical Cancer Research

Press Mentions

  • Long-Term Benefit of SABR for Operable Early-Stage NSCLC Shown in New Study
    Long-Term Benefit of SABR for Operable Early-Stage NSCLC Shown in New StudySeptember 13th, 2021
  • How Genprex Took an Abandoned Pipeline Drug and Turned It into Oncoprex, an Innovative Treatment for Non-Small Cell Lung Cancer
    How Genprex Took an Abandoned Pipeline Drug and Turned It into Oncoprex, an Innovative Treatment for Non-Small Cell Lung CancerOctober 17th, 2018
  • Genprex Reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer
    Genprex Reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung CancerApril 2nd, 2017
  • Join now to see all

Grant Support

  • P-5: Translation Of The 3p21.3 Gene FUS1 Into Pathway-Targeted Molecular TherapyNational Cancer Institute2008–2011
  • Developmental Research ProgramNational Cancer Institute2008–2011
  • Career Development ProgramNational Cancer Institute2008–2011
  • Restoration Of Apoptosis In CancerNational Cancer Institute1999–2003
  • Radiation Sensitivity/Apoptosis Induction In Cancer Cells--P53 RestorationNational Cancer Institute1999–2002
  • Modification Of Oncogene ExpressionNational Cancer Institute1992–1994
  • Training Of Academic Thoracic Surgical OncologistsNational Cancer Institute1988–1992
  • Tumor Antigens Expressed By Oncogene-Transformed CellsNational Cancer Institute1987–1991

Professional Memberships

Hospital Affiliations

Dr. Jack Roth, Dr. Jack Roth, MD, Dr. J Roth